Introduction of AI Drug Development Training Program

The Korea Pharmaceutical and Bio-Pharma Manufacturers Association announced on June 19 that it held the first AI Drug Discovery Advisory Committee of 2026 at the Parnas Hotel in Gangnam-gu, Seoul, on June 17.


At the meeting, there was consultation and discussion on ways to advance the education and promotion project for AI-powered drug development, as well as building an innovative ecosystem for AI drug discovery. The results of an on-site demand survey conducted among trainees were shared, and a new step-by-step AI drug development training program, to be launched this year, was introduced.

Pharma-Bio Association Holds First AI Drug Discovery Advisory Committee Meeting View original image

In his welcoming remarks, Noh Yeonhong, Chairman of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, stated, "AI is a core driver leading innovation across the entire drug development process. The Association is strengthening support for AI transformation (AX) in the industry and working to create a future-oriented R&D environment based on AI and automation technologies by establishing and utilizing autonomous laboratories (SDL)."


Participants agreed that educational initiatives should go beyond theoretical instruction and expand hands-on, practice-focused training and project-based programs that enable the application of the latest AI models to actual research. To achieve this, it was suggested that cooperation among AI companies, pharmaceutical and bio companies, and government-funded research institutes needs to be strengthened, and support projects should be enhanced to establish a foundation where outcomes from AI utilization can translate into real-world industrial settings.



The Association plans to launch a step-by-step AI drug development training program, starting with an introductory SDL special lecture in August.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing